Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02512692 · ClinicalTrials.gov registry record · NA
Gemcitabine-Cisplatin-90Y TARE for Unresectable Intrahepatic Cholangiocarcinoma
A NA study, sponsored by Medical University of South Carolina.
- Terminated
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT02512692 is a NA study that was terminated before completion, run by Medical University of South Carolina. The registered enrollment target is 6 participants.
The verdict
NCT02512692, a NA study, was terminated before completion, sponsored by Medical University of South Carolina.
- TERMINATED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and maximum tolerated dose (MTD) of 90 Y TARE (Y90) in combination with gemcitabine and cisplatin in patients with unresectable intrahepatic cholangiocarcinoma (ICC).
Interventions
- DRUG Cisplatin
- DRUG Gemcitabine
- DEVICE SIR-Spheres microspheres (Yttrium-90 Microspheres)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2015-07-21 |
| Est. Completion | 2021-03-19 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02512692
The ClinicalTrials.gov registry entry for NCT02512692 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT02512692 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02512692 about?
NCT02512692 is a clinical study titled "Gemcitabine-Cisplatin-90Y TARE for Unresectable Intrahepatic Cholangiocarcinoma". The purpose of this study is to determine the safety and maximum tolerated dose (MTD) of 90 Y TARE (Y90) in combination with gemcitabine and cisplatin in patients with unresectable intrahepatic cholangiocarcinoma (ICC).
What is the current status of trial NCT02512692?
This trial is currently terminated. It is a NA study. The enrollment target is 6 participants. The study started on 2015-07-21. Estimated completion is 2021-03-19.
What interventions are being tested in trial NCT02512692?
The interventions under investigation include: Cisplatin (DRUG), Gemcitabine (DRUG), SIR-Spheres microspheres (Yttrium-90 Microspheres) (DEVICE).
Who is sponsoring clinical trial NCT02512692?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.